Latest Development Activity News

Wildcat Resources has delivered robust lithium assay results from its Bolt Cutter Central discovery and Tabba Tabba project, while tripling its exploration strike length through a strategic tenement rights acquisition.

Forrestania Resources secured near-unanimous shareholder approval for its acquisition of the Edna May Project and a $310 million capital raising, clearing the path to expand its gold footprint in Western Australia.

Saturn Metals has significantly oversubscribed its Share Purchase Plan, raising $21.28 million against a $5 million target. Combined with a recent $100 million placement, the company now has $121.28 million to accelerate development of its Apollo Hill Gold Project in Western Australia.

Austral Gold nearly doubled its gold equivalent production in the first half of 2026, driven by the Casposo restart and Guanaco operations, delivering a US$15.5 million net profit and extending Guanaco’s mine life to 14 years.

Renegade Exploration has boosted and prolonged its loan facility to $2 million, using shares from its recent Carpentaria JV sale as additional security to support ongoing exploration.

Summerset Group Holdings posted a 92% jump in half-year net profit to NZ$171.4 million, driven by strong sales and disciplined cash management. The company also updated its dividend policy to align payouts with operating cash flow, reflecting its maturing portfolio and cautious growth approach.

Desane Group Holdings posted a statutory net profit after tax of just $0.02 million for FY26, down sharply from $3.32 million the previous year, while advancing key property developments and maintaining a strong balance sheet.

Kalina Power (ASX:KPO) swung to a AUD 15.8 million net profit in FY2026, driven by a CAD 18 million sale of megawatt allocation, lifting its balance sheet and cash reserves sharply.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.

Hawsons Iron Limited has closed its Share Purchase Plan raising $1.23 million through the issuance of 111.82 million shares at $0.011 each, accompanied by free attaching options. Directors contributed $90,000, reinforcing alignment with shareholders.

Desane Group Holdings projects FY26 EBIT between $0.9 million and $1.0 million, a steep drop from $5.4 million last year, ahead of audited results due by month-end.